Preferred Label : Linzagolix;
NCIt synonyms : Thieno(3,4-d)pyrimidine-5-carboxylic acid, 3-(5-((2,3-Difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-1,2,3,4-tetrahydro-2,4-dioxo-;
NCIt definition : An orally bioavailable gonadotropin-releasing hormone (GnRH or LHRH) receptor antagonist,
with potential hormone production inhibitory activity. Upon oral administration of
linzagolix, this agent competes with GnRH for receptor binding and inhibits GnRH receptor
signaling in the anterior pituitary gland, thereby inhibiting the secretion and release
of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the
inhibition of LH secretion prevents the release of testosterone. As a result, this
may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent
prostate cancer. In women, this prevents the production of estrogen by the ovaries
and may relieve symptoms from sex-hormone dependent diseases, such as pain associated
with endometriosis, heavy menstrual bleeding or uterine fibroids.;
UNII : 7CDW97HUEX;
InChIKey : BMAAMIIYNNPHAB-UHFFFAOYSA-N;
CAS number : 935283-04-8;
Molecule name : OBE2109; KLH-2109; KLH 2109;
NCI Metathesaurus CUI : CL551060;
Origin ID : C148479;
UMLS CUI : C5235403;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
